These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 19426125)

  • 1. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues.
    Brown NA
    Expert Opin Investig Drugs; 2009 Jun; 18(6):709-25. PubMed ID: 19426125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New NS5B polymerase inhibitors for hepatitis C.
    Legrand-Abravanel F; Nicot F; Izopet J
    Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs in development for chronic hepatitis C: a promising future.
    Pockros PJ
    Expert Opin Biol Ther; 2011 Dec; 11(12):1611-22. PubMed ID: 21995412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising candidates for the treatment of chronic hepatitis C.
    Walker MP; Yao N; Hong Z
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1269-80. PubMed ID: 12882616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future directions in therapy for chronic hepatitis C.
    Jensen DM; Ascione A
    Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection.
    Wyles DL
    Top HIV Med; 2010; 18(4):132-6. PubMed ID: 21107012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of current anti-HCV treatment regimens and possible future strategies.
    Neukam K; Macías J; Mira JA; Pineda JA
    Expert Opin Pharmacother; 2009 Feb; 10(3):417-33. PubMed ID: 19191679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
    Pawlotsky JM
    Hepatology; 2011 May; 53(5):1742-51. PubMed ID: 21374691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
    Chen SH; Tan SL
    Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C: current and future.
    Pawlotsky JM
    Curr Top Microbiol Immunol; 2013; 369():321-42. PubMed ID: 23463207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid progression of antiviral treatments of chronic hepatitis C virus infection.
    Pol S; Corouge M; Mallet V; Sogni P
    Minerva Gastroenterol Dietol; 2013 Jun; 59(2):161-72. PubMed ID: 23831907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis C virus: 25 years-old, the end?].
    Pol S
    Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Hepatitis B and C--current treatment and future therapeutic prospects.
    Müller C
    Wien Med Wochenschr; 2006 Jul; 156(13-14):391-6. PubMed ID: 16937041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of non-response to antiviral treatment in chronic hepatitis C.
    Chevaliez S; Asselah T
    Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S31-41. PubMed ID: 21742299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.